Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Masatsugu Moriwaki,1,2 Yoichiro Otake,2 Kaku Akamatsu,3 Tomo Okochi,4 Shigeki Hirano,4 Toshihiko Funahashi,5 Momoko Okuda,6 Hideaki Tabuse,6 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, 2Departmen...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-01-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/escitalopram-versus-paroxetine-controlled-release-in-major-depressive--peer-reviewed-article-NDT |
| _version_ | 1818421176528011264 |
|---|---|
| author | Kishi T Matsuda Y Matsunaga S Moriwaki M Otake Y Akamatsu K Okochi T Hirano S Funahashi T Okuda M Tabuse H Fujita K Iwata N |
| author_facet | Kishi T Matsuda Y Matsunaga S Moriwaki M Otake Y Akamatsu K Okochi T Hirano S Funahashi T Okuda M Tabuse H Fujita K Iwata N |
| author_sort | Kishi T |
| collection | DOAJ |
| description | Taro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Masatsugu Moriwaki,1,2 Yoichiro Otake,2 Kaku Akamatsu,3 Tomo Okochi,4 Shigeki Hirano,4 Toshihiko Funahashi,5 Momoko Okuda,6 Hideaki Tabuse,6 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, 2Department of Psychiatry, Okehazama Hospital, Toyoake, 3Department of Psychiatry, Jindai Clinic, Nagoya, 4Department of Psychiatry, Toyota Memorial Hospital, 5Department of Psychiatry, Jindai Hospital, Toyota, Aichi, 6Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD).Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being ≥20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events.Results: A total of 88 patients with MDD (males, 61.4%; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0% (escitalopram, 55.8%; paroxetine controlled release, 60.0%). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups.Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.Keywords: escitalopram, paroxetine controlled release, major depressive disorder, Hamilton Rating Scale for Depression, antidepressant |
| first_indexed | 2024-12-14T13:06:12Z |
| format | Article |
| id | doaj.art-e08792372efe44ce84e76d859348dd3c |
| institution | Directory Open Access Journal |
| issn | 1178-2021 |
| language | English |
| last_indexed | 2024-12-14T13:06:12Z |
| publishDate | 2017-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-e08792372efe44ce84e76d859348dd3c2022-12-21T23:00:19ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212017-01-01Volume 1311712530764Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trialKishi TMatsuda YMatsunaga SMoriwaki MOtake YAkamatsu KOkochi THirano SFunahashi TOkuda MTabuse HFujita KIwata NTaro Kishi,1 Yuki Matsuda,1 Shinji Matsunaga,1 Masatsugu Moriwaki,1,2 Yoichiro Otake,2 Kaku Akamatsu,3 Tomo Okochi,4 Shigeki Hirano,4 Toshihiko Funahashi,5 Momoko Okuda,6 Hideaki Tabuse,6 Kiyoshi Fujita,2 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, 2Department of Psychiatry, Okehazama Hospital, Toyoake, 3Department of Psychiatry, Jindai Clinic, Nagoya, 4Department of Psychiatry, Toyota Memorial Hospital, 5Department of Psychiatry, Jindai Hospital, Toyota, Aichi, 6Department of Psychiatry, Holy Cross Hospital, Toki, Gifu, Japan Objective: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD).Methods: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in patients with MDD (UMIN000011191). Patients with the diagnosis of moderate-to-severe MDD (a 17-item Hamilton Rating Scale for Depression [HAMD-17], with total score at baseline being ≥20) were recruited to participate in a parallel, randomized, controlled trial. The primary outcome for efficacy was an improvement in the 21-item HAMD (HAMD-21) total score at 24 weeks. The secondary outcomes were the response, remission, and discontinuation rates and the incidence of individual adverse events.Results: A total of 88 patients with MDD (males, 61.4%; mean age, 40.8±13.4 years) were recruited. The discontinuation rate was 58.0% (escitalopram, 55.8%; paroxetine controlled release, 60.0%). Both escitalopram and paroxetine controlled-release treatment groups exhibited significant reduction in the HAMD-21 total score at 2, 4, 8, 12, and 24 weeks from the baseline. However, there were no significant differences in the HAMD-21 total score, response rate, remission rate, and discontinuation rate at any time point between the groups. In addition, there were no significant differences in the incidence of any individual adverse events (eg, nausea, vomiting, and somnolence) between the treatment groups.Conclusion: Our results suggest that escitalopram and paroxetine controlled release had similar efficacy and safety profiles in patients with MDD. One of the primary limitations of this study is the small sample size.Keywords: escitalopram, paroxetine controlled release, major depressive disorder, Hamilton Rating Scale for Depression, antidepressanthttps://www.dovepress.com/escitalopram-versus-paroxetine-controlled-release-in-major-depressive--peer-reviewed-article-NDTescitalopramparoxetine controlled releasemajor depressive disorderHamilton Rating Scale for Depressionantidepressant |
| spellingShingle | Kishi T Matsuda Y Matsunaga S Moriwaki M Otake Y Akamatsu K Okochi T Hirano S Funahashi T Okuda M Tabuse H Fujita K Iwata N Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial Neuropsychiatric Disease and Treatment escitalopram paroxetine controlled release major depressive disorder Hamilton Rating Scale for Depression antidepressant |
| title | Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial |
| title_full | Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial |
| title_fullStr | Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial |
| title_full_unstemmed | Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial |
| title_short | Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial |
| title_sort | escitalopram versus paroxetine controlled release in major depressive disorder a randomized trial |
| topic | escitalopram paroxetine controlled release major depressive disorder Hamilton Rating Scale for Depression antidepressant |
| url | https://www.dovepress.com/escitalopram-versus-paroxetine-controlled-release-in-major-depressive--peer-reviewed-article-NDT |
| work_keys_str_mv | AT kishit escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT matsuday escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT matsunagas escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT moriwakim escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT otakey escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT akamatsuk escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT okochit escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT hiranos escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT funahashit escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT okudam escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT tabuseh escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT fujitak escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial AT iwatan escitalopramversusparoxetinecontrolledreleaseinmajordepressivedisorderarandomizedtrial |